HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and are Commonly Detected in Plasma from HIV-infected Humans

EBioMedicine

Volumn 2, Issue 10, 2015, Pages 1464-1477

  Williams, Katherine L ^a   Cortez, Valerie ^a,b   Dingens, Adam S ^a,b   Gach, Johannes S ^c   Rainwater, Stephanie ^a   Weis, Julie F ^a   Chen, Xuemin ^d   Spearman, Paul ^d   Forthal, Donald N ^c   Overbaugh, Julie ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADCC; Antibody; Breadth; C11; CD4 induced; CD4i; HIV; Potency; RF ADCC

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ARTICLE; CLADISTICS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEMORY CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS CELL INTERACTION; VIRUS LIKE AGENT; VIRUS LOAD; VIRUS NEUTRALIZATION; B LYMPHOCYTE SUBPOPULATION; BLOOD; CD4+ T LYMPHOCYTE; CLASSIFICATION; CROSS REACTION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; SERODIAGNOSIS; VIROLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, VIRAL; B-LYMPHOCYTE SUBSETS; CD4-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; NEUTRALIZATION TESTS;

EID: 84951908911     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.09.001     Document Type: Article

References (96)

1. Ackerman M.E., Alter G. Opportunities to exploit non-neutralizing HIV-specific antibody activity. Curr. HIV Res. 2013, 11:365-377. 10.2174/1570162X113116660058.
2. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28:413-444. 10.1146/annurev-immunol-030409-101256.
3. Burke B., Barnett S.W. Broadening our view of protective antibody responses against HIV. Curr HIV Res. 2007, 5:625-641. 10.2174/157016207782418533.
4. West A.P., Scharf L., Scheid J.F., Klein F., Bjorkman P.J., Nussenzweig M.C. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 2014, 156:633-648. 10.1016/j.cell.2014.01.052.
5. Forthal D.N., Landucci G., Daar E.S. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 2001, 75:6953-6961. 10.1128/JVI.75.15.6953-6961.2001.
6. Chung A.W., Navis M., Isitman G., Centre R., Finlayson R., Bloch M., et al. Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol. 2011, 24:171-175. 10.1089/vim.2010.0108.
7. Alpert M.D., Gorny M.K., Harvey J.D., Stamatatos L., Lauer W.A., Volsky B., et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIVmac251 challenge. PLoS Pathog. 2012, 8:e1002890. 10.1371/journal.ppat.1002890.s004.
8. Dugast A.-S., Stamatatos L., Tonelli A., Suscovich T.J., Licht A.F., Mikell I., et al. Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur. J. Immunol. 2014, 44:2925-2937. 10.1002/eji.201344305.
9. Hessell A.J., Hangartner L., Hunter M., Havenith C.E.G., Beurskens F.J., Bakker J.M., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007, 449:101-104. 10.1038/nature06106.
10. Hessell A.J., Poignard P., Hunter M., Hangartner L., Tehrani D.M., Bleeker W.K., et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009, 15:951-954. 10.1038/nm.1974.
11. Lewis G.K. Role of Fc-mediated antibody function in protective immunity against HIV-1. Immunology 2014, 142:46-57. 10.1111/imm.12232.
12. Banks N.D., Kinsey N., Clements J., Hildreth J.E.K. Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res. Hum. Retrovir. 2002, 18:1197-1205. 10.1089/08892220260387940.
13. Asmal M., Sun Y., Lane S., Yeh W., Schmidt S.D., et al. Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses. J. Virol. 2011, 85:5465-5475. 10.1128/JVI.00313-11.
14. Sun Y., Asmal M., Lane S., Permar S.R., Schmidt S.D., Mascola J.R., et al. Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J. Virol. 2011, 85:6906-6912. 10.1128/JVI.00326-11.
15. Bournazos S., Klein F., Pietzsch J., Seaman M.S., Nussenzweig M.C., Ravetch J.V. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 2014, 158:1243-1253. 10.1016/j.cell.2014.08.023.
16. Baum L.L., Cassutt K.J., Knigge K., Khattri R., Margolick J., Rinaldo C., et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 1996, 157:2168-2173.
17. Ahmad R., Sindhu S.T., Toma E., Morisset R., Vincelette J., Menezes J., et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 2001, 21:227-233.
18. Nag P., Kim J., Sapiega V., Landay A.L., Bremer J.W., Mestecky J., et al. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J. Infect. Dis. 2004, 190:1970-1978. 10.1086/425,582.
19. Lambotte O., Ferrari G., Moog C., Yates N.L., Liao H.-X., Parks R.J., et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009, 23:897-906. 10.1097/QAD.0b013e328329f97d.
20. Johansson S.E., Rollman E., Chung A.W., Center R.J., Hejdeman B., Stratov I., et al. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol. 2011, 24:359-368. 10.1089/vim.2011.0025.
21. Wren L.H., Chung A.W., Isitman G., Kelleher A.D., Parsons M.S., Amin J., et al. Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 2013, 138:116-123. 10.1111/imm.12016.
22. Lambotte O., Pollara J., Boufassa F., Moog C., Venet A., Haynes B.F., et al. High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. PLoS ONE 2013, 8:e74855. 10.1371/journal.pone.0074855.
23. Ahmad A., Morisset R., Thomas R., Menezes J. Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J. Acquir. Immune Defic. Syndr. 1994, 7:428-437.
24. Chung A.W., Navis M., Isitman G., Wren L., Silvers J., Amin J., et al. Activation of NK cells by ADCC antibodies and HIV disease progression. J. Acquir. Immune Defic. Syndr. 2011, 58:127-131. 10.1097/QAI.0b013e31822c62b9.
25. Milligan C., Richardson B.A., John-Stewart G., Nduati R., Overbaugh J. Passively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality. Cell Host Microbe 2015, 17:500-506. 10.1016/j.chom.2015.03.002.
26. Mabuka J., Nduati R., Odem-Davis K., Peterson D., Overbaugh J. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog. 2012, 8:e1002739. 10.1371/journal.ppat.1002739.s004.
27. Florese R.H., Van Rompay K.K.A., Aldrich K., Forthal D.N., Landucci G., Mahalanabis M., et al. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J. Immunol. 2006, 177:4028-4036. 10.4049/jimmunol.177.6.4028.
28. Dugast A.-S., Chan Y., Hoffner M., Licht A., Nkolola J., Li H., et al. Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodies. PLoS ONE 2014, 9. 10.1371/journal.pone.0097229.
29. Gómez-Román V.R., Patterson L.J., Venzon D., Liewehr D., Aldrich K., Florese R., et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 2005, 174:2185-2189. 10.4049/jimmunol.174.4.2185.
30. DeVico A., Fouts T., Lewis G.K., Gallo R.C., Godfrey K., Charurat M., et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17,477-17,482. 10.1073/pnas.0707399104.
31. Hidajat R., Xiao P., Zhou Q., Venzon D., Summers L.E., Kalyanaraman V.S., et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J. Virol. 2009, 83:791-801. 10.1128/JVI.01672-08.
32. Xiao P., Zhao J., Patterson L.J., Brocca-Cofano E., Venzon D., Kozlowski P.A., et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J. Virol. 2010, 84:7161-7173. 10.1128/JVI.00410-10.
33. Brocca-Cofano E., McKinnon K., Demberg T., Venzon D., Hidajat R., Xiao P., et al. Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine 2011, 29:3310-3319. 10.1016/j.vaccine.2011.02.066.
34. Barouch D.H., Liu J., Li H., Maxfield L.F., Abbink P., Lynch D.M., et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482:89-93. 10.1038/nature10766.
35. Forthal D.N., Gilbert P.B., Landucci G., Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 2007, 178:6596-6603. 10.4049/jimmunol.178.10.6596.
36. Haynes B.F., Gómez-Román V.R., Gilbert P.B., Patterson L.J., McElrath M.J., Venzon D., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012, 366:1275-1286. 10.1056/NEJMoa1113425.
37. Tomaras G.D., West A.P., Ferrari G., Diskin R., Shen X., Nussenzweig M.C., et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:9019-9024. 10.1073/pnas.1301456110.
38. Grunow R., Franke L., Hinkula J., Wahren B., Fenyö E.M., Jondal M., et al. Monoclonal antibodies to p24-core protein of HIV-1 mediate ADCC and inhibit virus spread in vitro. Clin. Diagn. Virol. 1995, 3:221-231.
39. Isitman G., Stratov I., Kent S.J. Antibody-dependent cellular cytotoxicity and NK cell-driven immune escape in HIV infection: implications for HIV vaccine development. Adv Virol. 2012, 2012:637208. 10.1155/2012/637,208.
40. Yamada T., Watanabe N., Nakamura T., Iwamoto A. Antibody-dependent cellular cytotoxicity via humoral immune epitope of Nef protein expressed on cell surface. J. Immunol. 2004, 172:2401-2406.
41. Tiemessen C.T., Shalekoff S., Meddows-Taylor S., Schramm D.B., Papathanasopoulos M.A., Gray G.E., et al. Cutting edge: unusual NK cell responses to HIV-1 peptides are associated with protection against maternal-infant transmission of HIV-1. J. Immunol. 2009, 182:5914-5918. 10.4049/jimmunol.0900419.
42. Pollara J., Bonsignori M., Moody M.A., Pazgier M., Haynes B.F., Ferrari G. Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses. Curr. HIV Res. 2013, 11:378-387.
43. Gach J.S., Leaman D.P., Zwick M.B. Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules. Curr. Top. Med. Chem. 2011, 11:2997-3021.
44. Guan Y., Pazgier M., Sajadi M.M., Kamin-Lewis R., Al-Darmarki S., Flinko R., et al. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E69-E78. 10.1073/pnas.1217609110.
45. Finnegan C.M., Berg W., Lewis G.K., DeVico A.L. Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion. J. Virol. 2001, 75:11096-11105. 10.1128/JVI.75.22.11096-11105.2001.
46. Acharya P., Tolbert W.D., Gohain N., Wu X., Yu L., Liu T., et al. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. J. Virol. 2014, 88:12895-12906. 10.1128/JVI.02194-14.
47. Veillette M., Desormeaux A., Medjahed H., Gharsallah N.E., Coutu M., et al. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J. Virol. 2014, 88:2633-2644. 10.1128/JVI.03230-13.
48. Ferrari G., Sellhorn G., Pollara J., Kraft Z., Kozink D., Caldwell Z., et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J. Virol. 2011, 85:7029-7036. 10.1128/JVI.00171-11.
49. Bonsignori M., Pollara J., Moody M.A., Alpert M.D., Chen X., Hwang K.K., et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 2012, 86:11,521-11,532. 10.1128/JVI.01023-12.
50. Madhavi V., Wren L.H., Center R.J., Gonelli C., Winnall W.R., Parsons M.S., et al. Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design. AIDS 2014, 28:1859-1870. 10.1097/QAD.0000000000000310.
51. Piantadosi A., Panteleeff D., Blish C.A., Baeten J.M., Jaoko W., McClelland R.S., et al. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 2009, 83:10269-10274. 10.1128/JVI.01149-09.
52. Bosch K.A., Rainwater S., Jaoko W., Overbaugh J. Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response. Virology 2010, 398:115-124. 10.1016/j.virol.2009.11.032.
53. Lavreys L., Baeten J.M., Overbaugh J., Panteleeff D.D., Chohan B.H., Richardson B.A., et al. Virus load during primary Human Immunodeficiency Virus (HIV) type 1 infection is related to the severity of acute HIV illness in Kenyan women. Clin. Infect. Dis. 2002, 35:77-81. 10.1086/340862.
54. Moore J.P., McCutchan F.E., Poon S.W., Mascola J., Liu J., Cao Y., et al. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J. Virol. 1994, 68:8350-8364.
55. Moore J.P., Willey R.L., Lewis G.K., Robinson J., Sodroski J. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J. Virol. 1994, 68:6836-6847.
56. Hicar M.D., Chen X., Briney B., Hammonds J., Wang J.-J., Kalams S., et al. Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV. J. Acquir. Immune Defic. Syndr. 2010, 54:223-235. 10.1097/QAI.0b013e3181dc98a3.
57. Tiller T., Alpert M.D., Meffre E., Harvey J.D., Yurasov S., Lauer W.A., et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 2008, 329:112-124. 10.1016/j.jim.2007.09.017.
58. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637. 10.1126/science.1207227.
59. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602. 10.1126/science.1207532.
60. Georgiev I.S., Doria-Rose N.A., Zhou T., Do Kwon Y., Staupe R.P., Moquin S., et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 2013, 340:751-756. 10.1126/science.1233989.
61. Hezareh M., Hessell A.J., Jensen R.C., van de Winkel J.G., Parren P.W. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J. Virol. 2001, 75:12161-12168. 10.1128/JVI.75.24.12161-12168.2001.
62. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 2001, 276:6591-6604. 10.1074/jbc.M009483200.
63. Goo L., Jalalian-Lechak Z., Richardson B.A., Overbaugh J. A combination of broadly neutralizing HIV-1 monoclonal antibodies targeting distinct epitopes effectively neutralizes variants found in early infection. J. Virol. 2012, 86:10857-10861. 10.1128/JVI.01414-12.
64. Gómez-Román V.R., Florese R.H., Patterson L.J., Peng B., Venzon D., Aldrich K., et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 2006, 308:53-67. 10.1016/j.jim.2005.09.018.
65. Blish C.A., Nguyen M.-A., Overbaugh J. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med. 2008, 5. 10.1371/journal.pmed.0050009.
66. Kramski M., Schorcht A., Johnston A.P.R., Lichtfuss G.F., Jegaskanda S., De Rose R., et al. Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. J. Immunol. Methods 2012, 384:51-61. 10.1016/j.jim.2012.07.006.
67. Corti D., Voss J., Gamblin S.J., Codoni G., Macagno A., Jarrossay D., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333:850-856. 10.1126/science.1205669.
68. Forthal D.N., Landucci G., Keenan B. Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res. Hum. Retrovir. 2001, 17:553-561. 10.1089/08892220151126661.
69. Florese R.H., Demberg T., Xiao P., Kuller L., Larsen K., Summers L.E., et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J. Immunol. 2009, 182:3718-3727. 10.4049/jimmunol.0803115.
70. Rosenberg Y., Sack M., Montefiori D., Forthal D., Mao L., Hernandez-Abanto S., et al. Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. PLoS ONE 2013, 8:e58724. 10.1371/journal.pone.0058724.
71. Pantophlet R., Ollmann Saphire E., Poignard P., Parren P.W.H.I., Wilson I.A., et al. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of Human Immunodeficiency Virus Type 1 gp120. J. Virol. 2003, 77:642-658. 10.1128/JVI.77.1.642-658.2003.
72. Wu X., Yang Z.-Y., Li Y., Hogerkorp C.-M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861. 10.1126/science.1187659.
73. Gach J.S., Quendler H., Tong T., Narayan K.M., Du S.X., Whalen R.G., et al. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. PLoS ONE 2013, 8:e72054. 10.1371/journal.pone.0072054.
74. Thali M., Moore J.P., Furman C., Charles M., Ho D.D., Robinson J., et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 1993, 67:3978-3988.
75. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289. 10.1126/science.1178746.
76. Hessell A.J., Rakasz E.G., Poignard P., Hangartner L., Landucci G., Forthal D.N., et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009, 5:e1000433. 10.1371/journal.ppat.1000433.
77. Blish C.A., Sather D.N., Sellhorn G., Stamatatos L., Sun Y., Srivastava I., et al. Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes. J. Virol. 2010, 84:2573-2584. 10.1128/JVI.01687-09.
78. Stanfield R.L., Gorny M.K., Williams C., Zolla-Pazner S., Wilson I.A. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure 2004, 12:193-204. 10.1016/j.str.2004.01.003.
79. Cardozo T., Swetnam J., Pinter A., Krachmarov C., Nadas A., Almond D., et al. Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies. AIDS Res. Hum. Retrovir. 2009, 25:441-450. 10.1089/aid.2008.0188.
80. Li L., Bosch K.A., Wang X.-H., Rainwater S., Banerjee S., Jaoko W., et al. Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject. PLoS ONE 2012, 7:e39534. 10.1371/journal.pone.0039534.s004.
81. Corti D., Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 2013, 31:705-742. 10.1146/annurev-immunol-032712-095916.
82. Ikuta K., Morita C., Miyake S., Ito T., Okabayashi M., Sano K., et al. Expression of human immunodeficiency virus type 1 (HIV-1) gag antigens on the surface of a cell line persistently infected with HIV-1 that highly expresses HIV-1 antigens. Virology 1989, 170:408-417.
83. Nishino Y., Ohki K., Kimura T., Morikawa S., Mikami T., Ikuta K. Major core proteins, p24s, of human, simian, and feline immunodeficiency viruses are partly expressed on the surface of the virus-infected cells. Vaccine 1992, 10:677-683.
84. Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 2006, 80:2515-2528. 10.1128/JVI.80.5.2515-2528.2006.
85. Tong T., Osawa K., Robinson J.E., Crooks E.T., Binley J.M. Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120. J. Virol. 2013, 87:9233-9249. 10.1128/JVI.01145-13.
86. Ray K., Mengistu M., Yu L., Lewis G.K., Lakowicz J.R., DeVico A.L. Antigenic properties of the HIV envelope on virions in solution. J. Virol. 2014, 88:1795-1808. 10.1128/JVI.03048-13.
87. Pancera M., Majeed S., Ban Y.-E.A., Chen L., Huang C.-C., Kong L., et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1166-1171. 10.1073/pnas.0911004107.
88. Poignard P., Moulard M., Golez E., Vivona V., Franti M., Venturini S., et al. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 2003, 77:353-365. 10.1128/JVI.77.1.353-365.2003.
89. Korber B., Gaschen B., Yusim K., Thakallapally R., Kesmir C., Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 2001, 58:19-42.
90. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., et al. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296:2354-2360. 10.1126/science.1070441.
91. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420:678-682. 10.1038/nature01188.
92. Finzi A., Tomaras G.D., Xiang S.-H., Ferrari G., Pacheco B., Shen X., et al. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol. Cell 2010, 37:656-667. 10.1016/j.molcel.2010.02.012.
93. Gohain N., Tolbert W.D., Acharya P., Yu L., Liu T., Zhao P., et al. Cocrystal structures of antibody N60-i3 and antibody JR4 in complex with gp120 define more cluster A epitopes involved in effective antibody-dependent effector function against HIV-1. J. Virol. 2015, 89:8840-8854. 10.1128/JVI.01232-15.
94. Mengistu M., Ray K., Lewis G.K., DeVico A.L. Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells. PLoS Pathog. 2015, 11:e1004772. 10.1371/journal.ppat.1004772.
95. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.-P., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470. 10.1038/nature10373.
96. Mouquet H., Scharf L., Euler Z., Liu Y., Eden C., Scheid J.F., et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E3268-E3277. 10.1073/pnas.1217207109.